Kang Mi Yeon, Lee Bo Bin, Ji Yong Ick, Jung Eun Hyun, Chun Ho-Kyung, Song Sang Yong, Park Seong-Eun, Park Joobae, Kim Duk-Hwan
Center for Genome Research, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Kangnam-Ku, Seoul, South Korea.
Cancer. 2008 Apr 15;112(8):1699-707. doi: 10.1002/cncr.23335.
CpG island hypermethylation has been reported at the promoter region of many tumor suppressor genes in colorectal cancers. However, there are significant interindividual differences in the degree of DNA methylation in colorectal cancers. The objective of the current study was to understand whether single nucleotide polymorphisms (SNPs) around the promoter of a gene are implicated in the interindividual differences of CpG island hypermethylation.
Promoter methylation of the p14(ARF) gene and messenger RNA (mRNA) expression levels of p14(ARF), DNA methyltransferase 1 (DNMT1), and DNMT3b were investigated by using methylation-specific polymerase chain reaction (PCR) analysis (MSP) and quantitative real-time PCR analysis in fresh tissues from 188 patients with colorectal cancer. SNPs around the p14(ARF) promoter were genotyped in DNA from peripheral blood lymphocytes in 300 healthy individuals and in 188 patients with colorectal cancer by using matrix-assisted laser desorption/ionization mass spectrometry.
p14(ARF) methylation was present in 61 of 188 colorectal cancers (32%). Fourteen SNPs among the 20 candidate SNPs were identified as monomorphic in the Korean population studied. Two individual SNPs (-4256 thymine to cytosine [T-->C] and -1477 guanine to adenine [G-->A]), which were in strong linkage disequilibrium (|D'|=0.99; correlation coefficient [r(2)]=0.95), were associated significantly with p14(ARF) methylation. Patients who had the CC variant at the-4256 locus or the AA variant at the -1477 locus had 2.42 times (95% confidence interval [95% CI], 1.07-5.46; P = .03) and 2.47 times (95% CI, 1.09-5.56; P= .03) greater risk of p14(ARF) methylation than patients who had the TT or GG homozygote, respectively, after adjusting for mRNA levels of DNMTs. Four major haplotypes were identified within a block (-4256 T-->C, -3631 T-->C, -1477 G-->A, and +20,188 T-->C). p14(ARF) promoter methylation also was associated significantly with the CCAT haplotype (odds ratio [OR], 8.31; 95% CI, 2.43-28.41; P= .0007) and the CTAC haplotype (OR, 9.71; 95% CI, 1.09-86.24; P= .04).
The current results suggested that SNPs around the p14(ARF) promoter region may be responsible for the interindividual susceptibility to p14(ARF) promoter methylation among individuals with colorectal cancer.
据报道,在结直肠癌中,许多肿瘤抑制基因的启动子区域存在CpG岛高甲基化。然而,结直肠癌中DNA甲基化程度存在显著的个体差异。本研究的目的是了解基因启动子周围的单核苷酸多态性(SNP)是否与CpG岛高甲基化的个体差异有关。
采用甲基化特异性聚合酶链反应(PCR)分析(MSP)和定量实时PCR分析,对188例结直肠癌患者新鲜组织中的p14(ARF)基因启动子甲基化以及p14(ARF)、DNA甲基转移酶1(DNMT1)和DNMT3b的信使RNA(mRNA)表达水平进行研究。利用基质辅助激光解吸/电离质谱法,对300名健康个体和188例结直肠癌患者外周血淋巴细胞DNA中的p14(ARF)启动子周围SNP进行基因分型。
188例结直肠癌中有61例(32%)存在p14(ARF)甲基化。在所研究的韩国人群中,20个候选SNP中的14个被鉴定为单态性。两个个体SNP(-4256位胸腺嘧啶突变为胞嘧啶[T→C]和-1477位鸟嘌呤突变为腺嘌呤[G→A])处于强连锁不平衡状态(|D'| = 0.99;相关系数[r(2)] = 0.95),与p14(ARF)甲基化显著相关。在调整DNMTs的mRNA水平后,-4256位点为CC变异型或-1477位点为AA变异型的患者发生p14(ARF)甲基化的风险分别是TT或GG纯合子患者的2.42倍(95%置信区间[95%CI],1.07 - 5.46;P = 0.03)和2.47倍(95%CI,1.09 - 5.56;P = 0.03)。在一个区域内(-4256 T→C、-3631 T→C、-1477 G→A和+20,188 T→C)鉴定出四种主要单倍型。p14(ARF)启动子甲基化也与CCAT单倍型(优势比[OR],8.31;95%CI,2.43 - 28.41;P = 0.0007)和CTAC单倍型(OR,9.71;95%CI,1.09 - 86.24;P = 0.04)显著相关。
目前的结果表明,p14(ARF)启动子区域周围的SNP可能是结直肠癌患者个体对p14(ARF)启动子甲基化易感性差异的原因。